Incyte and MorphoSys Report First Patient Dosing in P-III inMIND Study for Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Shots:

• The first patient has been dosed in the P-IIII inMIND study assessing the efficacy and safety of tafasitamab vs PBO in combination with lenalidomide and rituximab in patients with r/r FL and MZL
• The study is expected to enroll ~600 adults aged≥18yrs. with r/r FL or MZL. The 1EPs is PFS in the FL population and 2EPs are PFS and OS in the overall population as well as PET-CR at the EOT in the FL population
• Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting mAb and has received the US FDA’s ODD for FL

Click here to­ read full press release/ article | Ref: Business Wire | Image: Morphosys